OPUS GENETICS INC. -

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

21 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023

12 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

24 May 2023 16:05:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

15 May 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator

02 May 2023 08:30:00 By Nasdaq GlobeNewswire

Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

25 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

21 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

23 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

16 Feb 2023 08:30:01 By Nasdaq GlobeNewswire

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

13 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

25 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis

06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

07 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

04 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

02 Nov 2022 08:09:57 By Nasdaq GlobeNewswire

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

24 Oct 2022 08:56:52 By Nasdaq GlobeNewswire